How long can patients with advanced kidney cancer live?

Kidney cancer, especially renal cell carcinoma (RCC), is a common and challenging malignancy. According to the ** Cancer Society (ACS), more than 90% of kidney cancer cases are renal cell carcinoma, in which cancer cells mainly originate in the renal tubules. When renal cell cancer forms in the kidney, the way it grows and spreads can have a significant impact on a patient's life expectancy. The survival time of patients with intermediate and advanced kidney cancer is affected by many factors, including the spread of the cancer, the patient's age, health status, kidney cancer subtypes, and treatment effects. These factors form a complex ensemble that determines a patient's survival prospects.

Survival rates for renal cell carcinoma are generally considered low, but advances in treatment technology in recent years have given many patients new hope. Before knowing a patient's life expectancy, it is important to determine the stage of cancer at diagnosis. The stages of cancer are generally divided into four grades, with earlier diagnosis meaning better odds of survival. For example, patients with renal cell carcinoma detected in the first stage have a relatively high chance of survival with appropriate treatment; while in stages three and four, as the cancer spreads, the survival rate decreases significantly.

The biggest factor affecting survival rates for patients with renal cell carcinoma is the stage at which the disease is diagnosed. According to statistics, the five-year survival rate for stage III renal cell carcinoma patients is about 30%, while by stage IV, the survival rate drops to about 5%. This means that only a minority of patients diagnosed in stage 4 are still alive five years later. Although these numbers provide an overall estimate of survival, each patient's specific circumstances may vary, so these statistics cannot be relied upon solely.

In addition, the patient's overall health is also an important predictor. Older patients often have other health problems that may affect their response to treatment and their ability to survive. At the same time, the subtype of renal cell carcinoma also affects survival rate, and different types of renal cell carcinoma have different biological characteristics. The effectiveness of the treatment a patient receives after diagnosis is also a key factor. With the emergence of targeted drugs and immunotherapy, the survival time of many patients has been extended.

Although the survival rate of renal cell carcinoma is worrying, the development of medical technology has enabled many patients to obtain better treatment results. Emerging therapies such as targeted therapy and immunotherapy for kidney cancer have provided new hope for many patients. For patients with intermediate and advanced kidney cancer, it is very important to actively communicate with their doctors to understand their condition and available treatment options. The medical team can develop a personalized treatment plan based on the patient's specific situation and provide relevant information and support.

In short, the survival time of patients with intermediate and advanced renal cancer is a complex and individualized issue, which is affected by a variety of factors. Although statistics provide some guidance, specific survival expectations should be based on factors such as an individual's stage of diagnosis, overall health, and response to treatment. When facing kidney cancer, patients should maintain a positive attitude and proactively seek help from a professional medical team in order to obtain the best treatment effect and quality of life.

(Click to view an introduction to drugs for the treatment of kidney cancer)

References:

https://www.healthline.com/health/renal-cell-carcinoma-prognosis#treatment